Abstract

The overall objective of this contract is to evaluate control measures for infectious diseases other than AIDS. There are still many infectious diseases for which effective and highly safe vaccines and therapies have yet to be developed. Additionally, for some diseases improved vaccines are needed that will prevent infection and disease in age groups not currently protected and that will offer increased safety. New vaccine and drug candidates continue to be developed, spurred on by advances in the basic sciences. The capacity to evaluate these new and improved vaccine and therapy candidates in an efficient and expeditious manner is an essential element of the efforts of the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). This contract for a Vaccine and Treatment Evaluation Unit [VTEU] is an integral part of these efforts and supports Phase I and Phase II clinical trials of bacterial and viral vaccines, other biologicals, and drugs as preventative and therapeutic measures against infectious diseases in people of all ages and risk categories. In selected circumstances, Phase III vaccine trials may also be undertaken. Also of importance is the epidemiologic surveillance of pathogens that are of special interest to NIAID, and capacity to undertake limited, relevant, basic and preclinical research directly linked to vaccine biology and immunology.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
N01AI045252-004
Application #
2296302
Study Section
Project Start
1994-09-30
Project End
2001-09-29
Budget Start
1996-03-28
Budget End
1997-09-29
Support Year
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229

  Publications

Staat, Mary Allen; Rice, Marilyn A; Donauer, Stephanie et al. (2010) Estimating the rotavirus hospitalization disease burden and trends, using capture-recapture methods. Pediatr Infect Dis J 29:1083-6
Stockman, Lauren J; Staat, Mary A; Holloway, Michol et al. (2008) Optimum diagnostic assay and clinical specimen for routine rotavirus surveillance. J Clin Microbiol 46:1842-3
Blutt, Sarah E; Matson, David O; Crawford, Sue E et al. (2007) Rotavirus antigenemia in children is associated with viremia. PLoS Med 4:e121
Lee, Brian P; Azimi, Parvin H; Staat, Mary Allen et al. (2005) Nonmedical costs associated with rotavirus disease requiring hospitalization. Pediatr Infect Dis J 24:984-8
Zintz, Carmelann; Bok, Karin; Parada, Ester et al. (2005) Prevalence and genetic characterization of caliciviruses among children hospitalized for acute gastroenteritis in the United States. Infect Genet Evol 5:281-90
Cohen, Mitchell B; Nataro, James P; Bernstein, David I et al. (2005) Prevalence of diarrheagenic Escherichia coli in acute childhood enteritis: a prospective controlled study. J Pediatr 146:54-61
Weiss, Alison A; Patton, Angela K; Millen, Scott H et al. (2004) Acellular pertussis vaccines and complement killing of Bordetella pertussis. Infect Immun 72:7346-51
Vancott, John L; McNeal, Monica M; Choi, Anthony H C et al. (2003) The role of interferons in rotavirus infections and protection. J Interferon Cytokine Res 23:163-70
Bernstein, David I; Yan, Lihan; Treanor, John et al. (2003) Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 22:28-34
Treanor, John; Keitel, Wendy; Belshe, Robert et al. (2002) Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 20:1099-105

Showing the most recent 10 out of 21 publications